As of now, very few research studies have examined the effects of financial constraints on the short- and long-term performances of companies after their announcement of convertible bonds. Due to asymmetric information, previous studies consider issuance of convertible bonds as negative news. As a result, the short- and long-term performances of companies generally decline after their convertible bond announcement. This study argues that when companies have investment plans, they are expected to have higher future cash flows. They will become increasingly more valuable regardless of the fact that they raise funds through the issue of convertible bonds (due to financial constraints), positively affecting the performance of companies. The results indicate that financial constraints have no effect on short-term performance, but did have a significantly positive impact on the long-term performance of companies after their issuance of convertible bonds.

No abstract

No abstract

No abstract

It is of great significance to develop compounds that can be soluble or dispersible in water and simultaneously remain high fluorescent in aqueous media. Compounds with aggregation induced emission (AIE) have a great potential as cell imaging agents. In this paper, 4,4′,4′′,4′′′‐(ethene‐1,1,2,2‐tetrayl)tetrakis(N,N‐diethylaniline) (denoted as ETTDA) with AIE was designed and prepared. DSPE‐PEG‐2000 (1,2‐dipalmitoyl‐sn‐glycero‐3‐phosphoethanolamine‐N‐(polyethylene glycol)‐Folate (sodium salt)‐2000) coated ETTDA nanoparticles (NPs) were used for treatment of four different kinds of cancer cells (HCT‐116 (human colon cancer cell), A549 (human caucasian lung carcinoma), Hela (human cervical cancer cells) and A2780 (ovarian carcinoma cells)) and cytotoxicity investigation shows it is highly sensitive to Hela, moderate sensitive to A549 and A2780 but low sensitive to HCT‐116. Furthermore, cell migration of ETTDA nanoparticles (NPs) on Hela shows that ETTDA NPs are capable of inhibiting the migration of Hela in vitro, indicating its potential ability to interfere with the transfer of tumor in vivo.